Last reviewed · How we verify
NCT06124638
Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Panel to Support Home Use
NA trial testing Panbio™ COVID-19/Flu A&B Panel in COVID-19 in 624 participants. Completed in 3 April 2024.
3 April 2024
Quick facts
| Lead sponsor | Abbott Rapid Dx |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 624 |
| Start date | 4 December 2023 |
| Primary completion | 3 April 2024 |
| Estimated completion | 3 April 2024 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- Panbio™ COVID-19/Flu A&B Panel
Conditions studied
- COVID-19 — all drugs for COVID-19 →
- Influenza A — all drugs for Influenza A →
- Influenza Type B — all drugs for Influenza Type B →
Sponsor
Abbott Rapid Dx
Who can join
2 and older, any sex, with COVID-19 or Influenza A. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is designed to demonstrate the performance and usability of the the Panbio™ COVID-19/Flu A\&B Panel Self Test in the hands of patients/lay-users. Nasal swabs will be self-collected by subjects/lay-users who are symptomatic and suspected of viral respiratory infection. They will perform, read, and interpret the test result. The test is intended for nonprescription home use for qualitative detection of COVID-19, Influenza A antigen, and Influenza B antigen.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06124638
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COVID-19
Currently open trials in the same condition.
- NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
- NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
- NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
- NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
- NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting
Other Abbott Rapid Dx trials
Trials by the same sponsor.
- NCT07203183 — Dengue - Sample Collection Study Pakistan · not yet recruiting
- NCT06928129 — Clinical Feasibility of the BinaxNOW™ COVID-19/Flu A&B Combo in the Southern Hemisphere · NA · not yet recruiting
- NCT06492018 — Lay User Evaluation of the Panbio™ HCV Self Test in an EU Population · not yet recruiting
- NCT06395675 — Clinical Evaluation of the ID NOW™ CT/NG Test · NA · not yet recruiting
- NCT06127108 — Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Panel · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06124638 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Abbott Rapid Dx
- Last refreshed: 19 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06124638.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing